Evidence map›Paper›PMID 19072517›Full record

ReviewWomen's health (London, England)2008

Progesterone and breast cancer.

Carol A Lange, Douglas Yee

Open access · goldAbstract readReview
In one paragraph

Review in Women's health (London, England), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 93 citations in OpenAlex.

  1. Effects of aerobic exercise on premenopausal sex hormone levels: results of the WISER study, a randomized clinical trial in healthy, sedentary, eumenorrheic women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011
    Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Animals : an open access journal from MDPI · 2022
    Article
  15. Progesterone in gender-affirming therapy of trans women.World journal of biological chemistry · 2022
    Review
  16. Article
  17. Article
  18. Key to Life: Physiological Role and Clinical Implications of Progesterone.International journal of molecular sciences · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Carol A LangeUniversity of Minnesota, Cancer Center, Department of Medicine (Hematology, Oncology & Transplantation), 420 Delaware Street SE, MMC 806, MN 55455, USA. lange047@umn.edu
Douglas Yee
University of Minnesota · USUniversity of Minnesota Medical Center · US

Funding

Role of Phospho-Progesterone Receptors (PR) in Hormone Refractory Breast CancerR01CA159712 · NCI · UNIVERSITY OF MINNESOTA · PI LANGE, CAROL A · 2012 to 2016
$1.9M
Progestin and growth factor cross-talk in breast cancerR01CA123763 · NCI · UNIVERSITY OF MINNESOTA · PI LANGE, CAROL A · 2006 to 2010
$1.1M
PROGESTIN AND GROWTH FACTOR CROSS-TALK IN BREAST CANCERR01DK053825 · NIDDK · UNIVERSITY OF MINNESOTA TWIN CITIES · PI LANGE, CAROL ANN · 1997 to 2004
$975k
MAPKs Regulate Progesterone Receptors by SUMO ModulationR21CA116790 · NCI · UNIVERSITY OF MINNESOTA · PI LANGE, CAROL ANN · 2006 to 2007
$294k
NCI NIH HHS R01 CA123763NCI NIH HHS R01 CA159712NCI NIH HHS R21 CA116790NIDDK NIH HHS R01 DK053825
6 · The paper itself

Abstract

Progesterone is an ovarian steroid hormone that is essential for normal breast development during puberty and in preparation for lactation and breastfeeding. The actions of progesterone are primarily mediated by its high-affinity receptors, which include the classical progesterone receptor (PR)-A and -B isoforms, located in diverse tissues, including the brain, where progesterone controls reproductive behavior, and the breast and reproductive organs. Progestins are frequently prescribed for contraception or during postmenopausal hormone replacement therapy, in which progestins are combined with estrogen as a means to block estrogen-induced endometrial growth. The role of estrogen as a potent breast mitogen is undisputed, and inhibitors of the estrogen receptor and estrogen-producing enzymes (aromatases) are effective first-line cancer therapies. However, PR action in breast cancer is grossly understudied and remains controversial. Herein, we review existing evidence and discuss the challenges to defining a role for progesterone in breast cancer.

Indexed as

AnimalsBreastBreast NeoplasmsEstrogen Replacement TherapyFemaleHaplorhiniHumansMammary Glands, AnimalMammary Neoplasms, ExperimentalMiceProgesteroneProgestinsRatsReceptors, ProgesteroneProgesteroneProgestinsReceptors, Progesterone

Identifiers

PMID19072517
PMCPMC4038907
OpenAlexW2152635438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.